Clinical Trial Update: Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) [Phase 3]

View source ↗

Summary

Phase 3 open-label trial of EB-101 for recessive dystrophic epidermolysis bullosa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa
• Recessive Dystrophic Epidermolysis Bullosa

Drugs mentioned

• EB-101

Snippet

Sponsor: Abeona Therapeutics, Inc | Conditions: Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | Status: COMPLETED